FierceBiotech 20. Mai 2026 Immunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails
BioWorld 20. Mai 2026 Shanghai Institute of Materia Medica and Yantai New Drug Creation patent new DACs
Novo Nordisk 20. Mai 2026 50-60% of Danish Wegovy patients do not reach the maximum dose - medwatch.com
Pfizer 20. Mai 2026 Pfizer takes paediatric 25-valent pneumococcal vaccine to Phase III - FirstWord PHARMA
Edwards Lifesciences 20. Mai 2026 Edwards Lifesciences stock (US28176E1082): Guidance and revenue growth stay in focus - AD HOC NEWS
Moderna 20. Mai 2026 ROIV: Strong clinical progress and a $2.25B Moderna settlement drive robust financial position - TradingView
Endpoints News 20. Mai 2026 Parabilis reveals IPO plans the day after Regeneron deal as listings heat up
Endpoints News 20. Mai 2026 GHO Capital, CBC Group to merge, forming what could be the largest healthcare specialist investor
FierceBiotech 20. Mai 2026 Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push